Filing Details

Accession Number:
0001689813-19-000068
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-10-17 18:29:27
Reporting Period:
2019-10-15
Accepted Time:
2019-10-17 18:29:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1785732 Elyse Stock C/O Biohaven Pharmaceuticals, Inc., 215
Church Street
New Haven CT 06510
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2019-10-15 800 $10.82 800 No 4 M Direct
Common Shares Disposition 2019-10-15 800 $45.01 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Employee Stock Option (Right to Buy) Disposition 2019-10-15 800 $0.00 800 $10.82
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
36,200 2027-04-05 No 4 M Direct
Footnotes
  1. These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 - $45.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  3. The option, representing a right to purchase a total of 37,000 shares, became exercisable as to 18,500 shares on and prior to April 6, 2019 and becomes exercisable as to the remaining 18,500 shares on April 6, 2020, subject to the reporting person's continued service as of such date.